Sign In
Buy MRNA
$47.44
-4.15 (-8.04%)
At Close: Jun 05, 2026
Cathie Wood Just Bought This Struggling Stock After Its Billion-Dollar Quarterly Loss. Should You?
05:00am, Tuesday, 07'th Nov 2023
Cathie Wood is known for buying a stock when everyone else is selling it -- as long as the company's long-term prospects look good. Wood favors holding on for the long term, so she isn't bothered by s
Down 84% From Its Peak. Is It Finally Time to Buy Moderna?
06:18am, Sunday, 05'th Nov 2023
Moderna recently reported third-quarter results. The stock is down about 84% from its peak in 2021.
Moderna May Be Facing Its Toughest Moment Ever. Time to Sell?
05:00am, Saturday, 04'th Nov 2023
Moderna reported a billion-dollar loss in the third quarter and began downsizing its manufacturing infrastructure to match lower levels of vaccine demand. The company says coronavirus vaccine sales ma
Moderna (MRNA) Reports Q3 Earnings: What Key Metrics Have to Say
07:33pm, Friday, 03'rd Nov 2023
Although the revenue and EPS for Moderna (MRNA) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Str
Moderna CEO discusses earnings and how the company aims to break even by 2026
06:24pm, Thursday, 02'nd Nov 2023
While boasting a third-quarter revenue beat, biotech firm Moderna (MRNA) reported an overwhelmingly higher-than-expected loss of $9.53 per share. Its shares find themselves under pressure over weakeni
Moderna Shares Slide After Posting a Loss on Falling COVID-19 Vaccine Sales and Production
04:55pm, Thursday, 02'nd Nov 2023
Moderna (MRNA) shares tumbled over 6% Thursday after reporting a steep loss as the drug maker lost sales and cut back on making its COVID-19 vaccine, Spikevax, with demand waning.
Moderna, Inc. (MRNA) Q3 2023 Earnings Call Transcript
12:17pm, Thursday, 02'nd Nov 2023
Moderna, Inc. (NASDAQ:MRNA ) Q3 2023 Earnings Conference Call November 2, 2023 8:00 AM ET Company Participants Lavina Talukdar - Head of Investor Relations Stéphane Bancel - Chief Executive Officer A
Moderna stock plummets on 3Q loss and weak sales guidance
11:27am, Thursday, 02'nd Nov 2023
Moderna Therapeutics Inc (NASDAQ:MRNA) stock moved lower on Thursday after the drugmaker's weak full-year sales forecast and a significant loss for the third quarter overshadowed better-than-expected
Moderna CEO on Weak Sales Forecast, Future Acquisitions
10:07am, Thursday, 02'nd Nov 2023
Moderna CEO Stephane Bancel says he wants to 'reset the business cost structure' after the vaccine maker forecast a drop in sales for 2024. Speaking on "Bloomberg Markets," Bancel says higher interest
Moderna CEO Stephane Bancel on Q3 results
08:36am, Thursday, 02'nd Nov 2023
Moderna CEO Stephane Bancel joins 'Squawk Box' to discuss the company's quarterly earnings results, and more.
Moderna posts quarterly loss as company takes $1.3 billion write-down on unused Covid shots
08:03am, Thursday, 02'nd Nov 2023
CNBC's Becky Quick reports on the company's quarterly earnings results.
Moderna revenue tops expectations, expects to return to sales growth in 2025
06:35am, Thursday, 02'nd Nov 2023
Moderna on Thursday said it expected 2023 revenue of at least $6 billion, a decline reflecting weaker demand for COVID-19 vaccines this year, but that it would return to sales growth in 2025 and break
Moderna posts wider-than-expected loss, reins in full-year outlook
06:34am, Thursday, 02'nd Nov 2023
Moderna Inc. on Thursday reported a much wider-than-expected third quarter loss and reined in its full-year sales outlook as it resizes its pandemic-era manufacturing capacity and aims to break even i
Moderna posts quarterly loss as company takes $1.3 billion write-down on unused Covid shots
06:33am, Thursday, 02'nd Nov 2023
Moderna's total revenue for the third quarter still topped Wall Street's expectations despite plummeting demand for its Covid-19 shot.
Unlike Pfizer, Moderna can meet 2023 COVID forecast, analysts say
06:03am, Wednesday, 01'st Nov 2023
Moderna should hit the lower end of its sales target for this year as it only needs to tap a small portion of the private market with its COVID vaccine to reach that goal, according to industry analys
